| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abemaciclib for malignant pleural mesothelioma
|
Nardone, Valerio
|
|
|
23 |
6 |
p. e237
|
artikel
|
| 2 |
Abemaciclib for malignant pleural mesothelioma – Authors' reply
|
Fennell, Dean A
|
|
|
23 |
6 |
p. e238
|
artikel
|
| 3 |
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|
Wang, Jie
|
|
|
23 |
6 |
p. 739-747
|
artikel
|
| 4 |
African culture, traditional medicine, and cancer care
|
James, Peter Bai
|
|
|
23 |
6 |
p. 705-706
|
artikel
|
| 5 |
Assessment of the 2020 NICE criteria for preoperative radiotherapy in patients with rectal cancer treated by surgery alone in comparison with proven MRI prognostic factors: a retrospective cohort study
|
Lord, Amy C
|
|
|
23 |
6 |
p. 793-801
|
artikel
|
| 6 |
A swollen, discoloured thumb
|
Zhang, Peng
|
|
|
23 |
6 |
p. e313
|
artikel
|
| 7 |
Awake craniotomy as a mandatory part of the armamentarium of surgical neuro-oncologists
|
Krieg, Sandro M
|
|
|
23 |
6 |
p. 698-699
|
artikel
|
| 8 |
Cancer, health-care backlogs, and the cost-of-living crisis
|
The Lancet Oncology,
|
|
|
23 |
6 |
p. 691
|
artikel
|
| 9 |
Cancer in sub-Saharan Africa: a Lancet Oncology Commission
|
Ngwa, Wilfred
|
|
|
23 |
6 |
p. e251-e312
|
artikel
|
| 10 |
Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs
|
Bray, Freddie
|
|
|
23 |
6 |
p. 719-728
|
artikel
|
| 11 |
Cancer in sub-Saharan Africa: key research and action gaps
|
Johnson, Sonali Elizabeth
|
|
|
23 |
6 |
p. 703-705
|
artikel
|
| 12 |
Cancer in sub-Saharan Africa: the time to act is now
|
Gourd, Katherine
|
|
|
23 |
6 |
p. 701-702
|
artikel
|
| 13 |
Clinical features and outcomes of NAFLD-related hepatocellular carcinoma
|
Liu, Lei
|
|
|
23 |
6 |
p. e243
|
artikel
|
| 14 |
Clinical features and outcomes of NAFLD-related hepatocellular carcinoma – Authors' reply
|
Tan, Darren Jun Hao
|
|
|
23 |
6 |
p. e244
|
artikel
|
| 15 |
Closing the gap in cancer care in Kenya in 2022
|
Abdihamid, Omar
|
|
|
23 |
6 |
p. 715-716
|
artikel
|
| 16 |
Correction to Lancet Oncol 2020; 21: 699–709
|
|
|
|
23 |
6 |
p. e248
|
artikel
|
| 17 |
Correction to Lancet Oncol 2021; 22: 1250–64
|
|
|
|
23 |
6 |
p. e249
|
artikel
|
| 18 |
Correction to Lancet Oncol 2022; 23: e218–28
|
|
|
|
23 |
6 |
p. e249
|
artikel
|
| 19 |
COVID-19 vaccine effectiveness in patients with cancer: remaining vulnerabilities and uncertainties
|
Kuderer, Nicole M
|
|
|
23 |
6 |
p. 693-695
|
artikel
|
| 20 |
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy
|
Bomze, David
|
|
|
23 |
6 |
p. e245
|
artikel
|
| 21 |
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply
|
André, Thierry
|
|
|
23 |
6 |
p. e246
|
artikel
|
| 22 |
Economic crisis in Sri Lanka causing cancer drug shortage
|
Das, Manjulika
|
|
|
23 |
6 |
p. 710
|
artikel
|
| 23 |
Effect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a propensity score-matched analysis of an international, multicentre, cohort study
|
Gerritsen, Jasper K W
|
|
|
23 |
6 |
p. 802-817
|
artikel
|
| 24 |
Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma
|
Huang, Guan-Jiang
|
|
|
23 |
6 |
p. e239
|
artikel
|
| 25 |
Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma
|
Liu, Chieh-Min
|
|
|
23 |
6 |
p. e240
|
artikel
|
| 26 |
Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma – Authors' reply
|
Tang, Ling-Long
|
|
|
23 |
6 |
p. e241
|
artikel
|
| 27 |
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
|
Zauderer, Marjorie G
|
|
|
23 |
6 |
p. 758-767
|
artikel
|
| 28 |
Fidel Rubagumya—founder of Rwanda Cancer Relief
|
Gourd, Elizabeth
|
|
|
23 |
6 |
p. 716-717
|
artikel
|
| 29 |
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
|
Motzer, Robert
|
|
|
23 |
6 |
p. 768-780
|
artikel
|
| 30 |
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial
|
Kater, Arnon P
|
|
|
23 |
6 |
p. 818-828
|
artikel
|
| 31 |
New coalition to increase access to cancer medicines in LMICs
|
Burki, Talha Khan
|
|
|
23 |
6 |
p. e250
|
artikel
|
| 32 |
New United Arab Emirates representative joins WHO regional palliative care expert network
|
Das, Manjulika
|
|
|
23 |
6 |
p. 712
|
artikel
|
| 33 |
NICE 2020 guideline for the management of colorectal cancer
|
Davies, Justin
|
|
|
23 |
6 |
p. e247
|
artikel
|
| 34 |
Oncology specialists' perspective on caring for patients with cancer during the early days of war in Kyiv, Ukraine
|
Barakat, Philipp
|
|
|
23 |
6 |
p. 713-715
|
artikel
|
| 35 |
On the ROMANA 1 and 2 studies on anamorelin
|
Schuler, Ulrich S
|
|
|
23 |
6 |
p. e236
|
artikel
|
| 36 |
Personalised care for high-risk rectal cancer: does one size fit all?
|
Hupkens, Britt J P
|
|
|
23 |
6 |
p. 697-698
|
artikel
|
| 37 |
Philippa Kibugu-Decuir—founder of Breast Cancer Initiative East Africa
|
Gourd, Elizabeth
|
|
|
23 |
6 |
p. 717-718
|
artikel
|
| 38 |
President Macron's re-election and cancer research and care in France
|
Casassus, Barbara
|
|
|
23 |
6 |
p. 711
|
artikel
|
| 39 |
Preventing cancer and achieving optimal oncology outcomes in sub-Saharan Africa
|
Abubakar, Ibrahim
|
|
|
23 |
6 |
p. 708-709
|
artikel
|
| 40 |
Rays of Hope: the IAEA ups its commitment to cancer care
|
Grossi, Rafael Mariano
|
|
|
23 |
6 |
p. 702-703
|
artikel
|
| 41 |
Religion, cancer, and sub-Saharan African health systems
|
Olivier, Jill
|
|
|
23 |
6 |
p. 706-708
|
artikel
|
| 42 |
The future of precise cancer chronotherapeutics
|
Innominato, Pasquale F
|
|
|
23 |
6 |
p. e242
|
artikel
|
| 43 |
Time-limited, chemotherapy-free treatment comes of age in chronic lymphocytic leukaemia
|
Molica, Stefano
|
|
|
23 |
6 |
p. 699-701
|
artikel
|
| 44 |
Tiragolumab and atezolizumab in patients with PD-L1 positive non-small-cell lung cancer
|
Recondo, Gonzalo
|
|
|
23 |
6 |
p. 695-697
|
artikel
|
| 45 |
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
|
Cho, Byoung Chul
|
|
|
23 |
6 |
p. 781-792
|
artikel
|
| 46 |
Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer–Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa: a prospective cohort study
|
Foerster, Milena
|
|
|
23 |
6 |
p. 729-738
|
artikel
|
| 47 |
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study
|
Lee, Lennard Y W
|
|
|
23 |
6 |
p. 748-757
|
artikel
|
| 48 |
Validating chemoimmunotherapy in small-cell lung cancer
|
Smith, Katherine E R
|
|
|
23 |
6 |
p. 692-693
|
artikel
|
Tijdschrift beschrijving